More Accurate, Perhaps Cheaper, Clinical Data
Executive Summary
In the post-Vioxx era of increased scrutiny into clinical data, spiralling trial costs and a growing mistrust of drug firms' motives, the advantages of electronic diaries for use in clinical trials begin to look clearer. Their adoption has mirrored the industry's uptake of electronic data capture (EDC) systems more broadly: painfully slow until recently, but finally taking off.
You may also be interested in...
Making Clinical Trials More Efficient
Drug firms need to conduct more, bigger, and better-monitored trials. They also need to cut costs. Electronic data capture presents a possible, but far from straightforward, solution.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.